Identification of Susceptibility Loci in a Mouse Model of KRASG12D-Driven Pancreatic Cancer

被引:3
|
作者
Jorgenson, Tonia C. [1 ]
Williams, Bret R. [1 ]
Wendland, Allyson [2 ]
Bilger, Andrea [1 ]
Sandgren, Eric P. [2 ]
Drinkwater, Norman R. [1 ]
机构
[1] Univ Wisconsin, McArdle Lab Canc Res, Sch Med & Publ Hlth, Madison, WI 53706 USA
[2] Univ Wisconsin, Dept Pathobiol Sci, Sch Vet Med, Madison, WI 53706 USA
关键词
INTRAEPITHELIAL NEOPLASIA; ADENOCARCINOMA; CLASSIFICATION; TRANSFORMATION; CONSENSUS; MODIFIER; DISTAL;
D O I
10.1158/0008-5472.CAN-09-3980
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Genetic background affects susceptibility to pancreatic ductal adenocarcinoma in the Ela-KRAS(G12D) mouse model. In this model, KRAS oncogene expression is driven by an elastase promoter in acinar cells of the pancreas on an FVB/NTac (FVB) background [FVB-Tg(Ela-KRAS(G12D))] with the transgene carried on the Y chromosome. Through linkage analysis of crosses between the C57BL/6J (B6), BALB/cJ (BALB), and DBA/2J (D2) inbred strains of mice and resistant FVB-Tg(Ela-KRAS(G12D)), we have identified six susceptibility loci that affect mean preinvasive lesion multiplicity. Markers on chromosome 2 segregated with high tumor multiplicity in all three strains; these loci were designated Prsq1-3 (pancreatic ras susceptibility quantitative trait loci 1-3; combined F2 and N2 LODW, 6.0, 4.1, and 2.7, respectively). Susceptibility loci on chromosome 4, designated Prsq4 and Prsq5, were identified in crosses between FVB transgenic mice and B6 or BALB mice (combined F2 and N2 LODW, 3.6 and 2.9, respectively). A marker on chromosome 12 segregated with tumor multiplicity in a BALB x FVB-Tg(Ela-KRAS(G12D)) cross and was designated Prsq6 (LODW, similar to 2.5). B6-Chr YFVB-Tg(Ela-KRASG12D) and BALB-Chr YFVB-Tg(Ela-KRASG12D) consomics, which carry the KRAS transgene on the FVB Y chromosome on an otherwise inbred B6 or BALB background, developed similar to 4-fold (B6) and similar to 10-fold (BALB) more lesions than FVB-Tg(Ela-KRAS(G12D)) mice. By 12 months of age, 10% of BALB-Chr YFVB-Tg(Ela-KRASG12D) mice developed invasive carcinomas. Our findings provide evidence that regions of chromosomes 2, 4, and 12 influence the development and progression of pancreatic neoplasms initiated by an oncogenic allele of KRAS in mice. Cancer Res; 70(21); 8398-406. (C) 2010 AACR.
引用
收藏
页码:8398 / 8406
页数:9
相关论文
共 50 条
  • [21] Activated glucocorticoid signaling in pancreatitis contributes to acinar-to-ductal metaplasia and KrasG12D-driven tumorigenesis
    Lin, Pei-Yu
    Su, Chien-Chang
    Hsieh, Chi-Che
    Shen, Chia-Ning
    CANCER RESEARCH, 2015, 75
  • [22] Elevated expression of the V-ATPase D2 subunit triggers increased energy metabolite levels in KrasG12D-driven cancer cells
    Yang, Jigang
    Guo, Feihu
    Yuan, Leilei
    Lv, Guangxin
    Gong, Jianhua
    Chen, Jing
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2019, 120 (07) : 11690 - 11701
  • [23] The Mouse Model of Pancreatic Cancer Atlas (MMPCA) for classification of pancreatic cancer lesions: A large histological investigation of the Ptf1aCre/+; LSL-KrasG12D/+ transgenic mouse model of pancreatic cancer
    Veite-Schmahl, Michelle J.
    Rivers, Adam C.
    Regan, Daniel P.
    Kennedy, Michael A.
    PLOS ONE, 2017, 12 (11):
  • [24] Addition of metabolomics to the omics spectrum for cancer biomarker development– demonstration with the KrasG12D mouse model for pancreatic carcinoma
    Evagelia C. Laiakis
    Joseph J. LaConti
    Amrita Cheema
    Anton Wellstein
    Albert J. Fornace
    BMC Genomics, 15 (Suppl 2)
  • [25] Critical requirement of SOS1 for tumor development and microenvironment modulation in KRASG12D-driven lung adenocarcinoma
    Fernando C. Baltanás
    Rósula García-Navas
    Pablo Rodríguez-Ramos
    Nuria Calzada
    Cristina Cuesta
    Javier Borrajo
    Rocío Fuentes-Mateos
    Andrea Olarte-San Juan
    Nerea Vidaña
    Esther Castellano
    Eugenio Santos
    Nature Communications, 14
  • [26] Inactivation of Rbx1 E3 ligase suppresses KrasG12D-driven lung tumorigenesis
    Li, Yanan
    Wu, Di
    Li, Haomin
    Sun, Yi
    MEDCOMM, 2023, 4 (04):
  • [27] Acceleration of Pancreatic Cancer Development in the Conditional KrasG12D Mouse Model by a High Fat and High Calorie Diet
    Moro, A.
    Lugea, A.
    Dawson, D. W.
    Pandol, S.
    Gukovskaya, A.
    Rozengurt, E.
    Hines, O. J.
    Go, V. L. W.
    Eibl, G.
    PANCREAS, 2012, 41 (08) : 1388 - 1388
  • [28] Calorie restriction delays the progression of lesions to pancreatic cancer in the LSL-KrasG12D; Pdx-1/Cre mouse model of pancreatic cancer
    Lanza-Jacoby, Susan
    Yan, Guang
    Radice, Glenn
    LePhong, Christopher
    Baliff, Jeffrey
    Hess, Rachael
    EXPERIMENTAL BIOLOGY AND MEDICINE, 2013, 238 (07) : 787 - 797
  • [29] Deciphering acquired resistance to KRASG12D inhibition in a mouse model of pancreatic ductal adenocarcinoma
    Dilly, Julien
    Abbassi, Laleh
    Hennessey, Connor J.
    Uribe, Giselle A.
    Parent, Brendan
    Yang, Annan
    Kapner, Kevin S.
    Li, Ziyue
    Dasgupta, Shatavisha
    Jordan, Alexander
    Hoffman, Megan T.
    Qiang, Li
    Hambitzer, Felix P.
    Chugh, Seema
    Shalek, Alex K.
    Dougan, Stephanie K.
    Wolpin, Brian M.
    Nowak, Jonathan A.
    Raghavan, Srivatsan
    Winter, Peter S.
    Aguirre, Andrew J.
    CANCER RESEARCH, 2024, 84 (02)
  • [30] Modulation of Mutant KrasG12D-Driven Lung Tumorigenesis In Vivo by Gain or Loss of PCDH7 Function
    Zhou, Xiaorong
    Padanad, Mahesh S.
    Evers, Bret M.
    Smith, Bethany
    Novaresi, Nicole
    Suresh, Shruthy
    Richardson, James A.
    Stein, Emily
    Zhu, Jingfei
    Hammer, Robert E.
    O'Donnell, Kathryn A.
    MOLECULAR CANCER RESEARCH, 2019, 17 (02) : 594 - 603